Kalaris Therapeutics (KLRS) Change in Interest Receivables (2019 - 2024)
Kalaris Therapeutics (KLRS) posted quarterly Change in Interest Receivables of -$53000.0 for Q4 2024, down 89.29% year-over-year from -$494666.7 in Q1 2024, and down 23.26% quarter-over-quarter from -$43000.0 in Q3 2024.
Kalaris Therapeutics (KLRS) Change in Interest Receivables (2019 - 2024) Analysis & Trends
Kalaris Therapeutics' Change in Interest Receivables history runs 6 years deep, the most recent figure standing at -$53000.0 for Q4 2024.
- In Q4 2024, Change in Interest Receivables fell 89.29% year-over-year to -$53000.0; the TTM figure through Dec 2024 stood at -$206000.0 (down 520.41% YoY), while the FY2024 annual figure was -$206000.0, down 520.41% from the prior year.
- Change in Interest Receivables for Q4 2024 stood at -$53000.0, down from -$43000.0 in the prior quarter.
- The five-year high for Change in Interest Receivables was $364000.0 in Q3 2020, with the low at -$258000.0 in Q3 2021.
- The 5-year median for Change in Interest Receivables is -$35500.0 (2023), against an average of -$13100.0.
- The sharpest annual moves came in 2020 and 2021: Change in Interest Receivables jumped 613.73% in 2020, then plunged 460.71% in 2021.
- Kalaris Therapeutics' Change in Interest Receivables stood at $28000.0 in 2020, then slumped by 460.71% to -$101000.0 in 2021, then fell by 2.97% to -$104000.0 in 2022, then soared by 73.08% to -$28000.0 in 2023, then sank by 89.29% to -$53000.0 in 2024.
- Business Quant data shows KLRS's Change in Interest Receivables at -$53000.0 in Q4 2024, -$43000.0 in Q3 2024, and -$84000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -53,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Jun 30, 2024 | -84,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -28,000.00 |
| Sep 30, 2023 | 128,000.00 |
| Jun 30, 2023 | -138,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Dec 31, 2022 | -104,000.00 |
| Sep 30, 2022 | 170,000.00 |
| Jun 30, 2022 | -81,000.00 |
| Mar 31, 2022 | 122,000.00 |
| Dec 31, 2021 | -101,000.00 |
| Sep 30, 2021 | -258,000.00 |
| Jun 30, 2021 | -60,000.00 |
| Mar 31, 2021 | 19,000.00 |
| Dec 31, 2020 | 28,000.00 |
| Sep 30, 2020 | 364,000.00 |
| Jun 30, 2020 | -253,000.00 |
| Mar 31, 2020 | 49,000.00 |